An overview of Compassionate Use Programs in the European Union member states
Open Access
- 1 January 2016
- journal article
- review article
- Published by International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA) in Intractable & Rare Diseases Research
- Vol. 5 (4) , 244-254
Abstract
The past decade witnessed rapid development of novel drugs and therapeutic biological agents. The marketing authorization for novel therapies is often time consuming and distressing for patients. Earlier clinical trials were the only way to access new drugs under development. However, not every patient meets the enrolment criteria, and participation is difficult for patients with life-threatening, long-lasting or seriously debilitating diseases like rare diseases. Early access programs like "Compassionate Use Program (CUP)" have generated alternative channels for such patients. The European Medical Agency provides regulations and recommendations for compassionate use, upon which every European Union (EU) member state has developed its own rules and regulations. Despite previous reviews and studies, the available information is limited and gaps exist. This literature review explores CUP in 28 EU member states. Data was collected through literature review and use of country-specific search terms from the healthcare domain. Data sources were not limited to databases and articles published in journals, but also included grey literature. The results implied that CUP was present in 20 EU member states (71%). Of 28 EU states, 18 (~64%) had nationalized regulations and processes were well-defined. Overall, this review identified CUP and its current status and legislation in 28 EU member states. The established legislation for CUP in the EU member states suggest their willingness to adopt processes that facilitate earlier and better access to new medicines. Further research and periodic reviews are warranted to understand the contemporary and future regulatory trends in early access programs.Keywords
This publication has 12 references indexed in Scilit:
- Early access programs: Benefits, challenges, and key considerations for successful implementationPerspectives in Clinical Research, 2016
- Compassionate use of orphan drugsOrphanet Journal of Rare Diseases, 2015
- Rare diseases and orphan drugs: Latvian storyOrphanet Journal of Rare Diseases, 2014
- Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing?PharmacoEconomics, 2013
- State of the art of rare disease activities in Europe: a EUCERD perspectiveOrphanet Journal of Rare Diseases, 2012
- Compassionate use of medicinal products in Europe: current status and perspectivesBulletin of the World Health Organization, 2011
- Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countriesTrials, 2010
- Review of the safety and efficacy of imiglucerase treatment of Gaucher diseaseBiologics: Targets and Therapy, 2009
- Review of the safety and efficacy of imiglucerase treatment of Gaucher diseaseBiologics: Targets and Therapy, 2009
- Implementing a pre-launch named patient programme: Evidence of increased market shareJournal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing, 2008